48 results on '"Reneau, John C"'
Search Results
2. Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
3. Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma
4. Presenting features of indolent primary cutaneous B-cell lymphomas: Distinguishing clinical and histopathologic features
5. Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors
6. Selective Inhibition of Interleukin-2 Inducible T Cell Kinase (ITK) Enhances Anti-Tumor Immunity in Association with Th1-skewing, Cytotoxic T cell Activation, and Reduced T Cell Exhaustion
7. Data from Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma
8. Supplementary Data from Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma
9. Supplementary Figure from Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma
10. A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
11. BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis
12. Nanochip Technology for Monitoring Chemotherapy Response Using Extracellular RNAs and Proteins in Patient Plasma with Diffuse Large B-Cell Lymphoma As Biomarkers
13. ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas
14. TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo
15. Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy
16. CD3e-immunotoxin spares CD62Llo Tregs and reshapes organ-specific T-cell composition by preferentially depleting CD3ehi T cells
17. Mycosis Fungoides and Sézary Syndrome
18. Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas
19. Comparison of CD3e Antibody and CD3e-sZAP Immunotoxin Treatment in Mice Identifies sZAP as the Main Driver of Vascular Leakage
20. Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions
21. Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients
22. Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias
23. Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma
24. Siltuximab Prophylaxis Prior to Standard of Care CD19 Directed Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: Interim Results from a Phase I Clinical Trial
25. A Pilot Phase I Trial of IL-21 Expanded Ideal-Donor Natural Killer (NK) Cells in Combination with Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas (CTCL) or Adult T-Cell Leukemia/Lymphomas (ATLL)
26. Outcomes of Patients with Diffuse Large B Cell and High-Grade B Cell Lymphomas with Synchronous CNS and Systemic Involvement at Diagnosis Treated with High-Dose Methotrexate and R-CHOP: A Single-Center Retrospective Study
27. Survival Analysis of Patients with T-Cell Lymphoma or T-Cell Large Granular Leukemia and Concomitant Plasma Cell Dyscrasias
28. 47-Year-Old Man With Pruritus
29. CD3e-immunotoxin spares CD62Llo Tregs and reshapes organ-specific T-cell composition by preferentially depleting CD3ehi T cells.
30. Mogamulizumab exhibits synergistic activity in combination with allogeneic, IL21- expanded, natural killer (NK) cells against T-cell lymphoma
31. Novel therapies targeting cutaneous T cell lymphomas and their microenvironment
32. Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL): Adding Steam to ASCT
33. Spontaneous Regression of High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements: Case Report and Literature Review
34. A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma
35. Autologous stem cell transplant in first remission for transformed indolent non‐Hodgkin lymphoma: additional data to guide practice
36. Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial
37. Interleukin-2-Inducible T-Cell Kinase (ITK) Inhibitors for the Treatment of T-Cell Lymphoproliferative Disorders
38. 492 - Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL): Adding Steam to ASCT
39. Postinfusion PD-1+CD8+CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
40. Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial
41. GATA-3 Dependent Gene Transcription Is Impaired upon HDAC Inhibition
42. Differences in Observed Toxicities for Adolescent and Young Adult Patients with Aggressive Mature B-Cell Lymphomas Treated at Adult Versus Pediatric Cancer Center - a Comparative Cohort Study
43. Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
44. Gemcitabine and Liposomal Doxorubicin (GemDox) for the Treatment of Relapsed and Refractory T-Cell Lymphomas
45. Abstract 201: The combination treatment of TNF-α and poly (dA:dT) preactivated hMSCs with doxorubicin enhances antitumorigenic activity
46. Preactivation of Human MSCs with TNF-α Enhances Tumor-Suppressive Activity
47. CD3e-immunotoxin spares CD62L lo Tregs and reshapes organ-specific T-cell composition by preferentially depleting CD3e hi T cells.
48. Integrins and proximal signaling mechanisms in cardiovascular disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.